Flow cytometry assay modifications: Recommendations for method validation based on CLSI H62 guidelines
- 21 August 2024
- journal article
- research article
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 108 (3) , 252-266
Abstract
The Clinical and Laboratory Standards Institute (CLSI) H62—Validation of Assays Performed by Flow Cytometry guideline, released in 2021, provides recommendations for platform workflow and quality system essentials, instrument setup and standardization, assay development and optimization and fit‐for‐purpose analytical method validation. In addition, CLSI H62 includes some recommendations for the validation strategies after a validated flow cytometric method has been modified. This manuscript builds on those recommendations and discusses the impact of different types of assay modifications on assay performance. Recommendations regarding which validation parameters to evaluate depending on the type of modification are provided. The impact of assay modification on the assay's intended use is discussed. When recommending minor deviations from the CLSI H62 process for a laboratory‐initiated assay revision (e.g., specimen numbers for sensitivity, specificity, or precision studies), a rationale based on expert opinion is provided with the understanding that not every laboratory, assay type, and circumstance can be comprehensively addressed in this paper. These recommendations are meant as a practical recommendation and are not intended to be restrictive, prescriptive, or understood as necessarily sufficient to meet every specific requirement from regulatory bodies (e.g., FDA or New York State Department of Health).Keywords
This publication has 13 references indexed in Scilit:
- Establishing NK-Cell Receptor Restriction by Flow Cytometry and Detecting Potential NK-Cell Clones of Uncertain SignificanceLaboratory Investigation, 2023
- Flow cytometric method transfer: Recommendations for best practiceCytometry Part B: Clinical Cytometry, 2020
- International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trialsLeukemia, 2020
- Flow Cytometric Monitoring for Residual Disease in B Lymphoblastic Leukemia Post T Cell Engaging Targeted TherapiesCurrent Protocols in Cytometry, 2018
- Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation projectCytometry Part B: Clinical Cytometry, 2018
- Minimal residual disease analysis in myeloma – when, why and whereLeukemia & Lymphoma, 2017
- Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myelomaLeukemia, 2017
- A novel flow cytometric assay for detection of residual disease in patients with B‐lymphoblastic leukemia/lymphoma post anti‐CD19 therapyCytometry Part B: Clinical Cytometry, 2016
- Assessment of minimal residual disease in myeloma and the need for a consensus approachCytometry Part B: Clinical Cytometry, 2015
- CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high‐risk diseaseBritish Journal of Haematology, 2003